Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

PRLD · Nasdaq

Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Prelude Therapeutics Incorporated in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 77 days

EPS estimate

0.14

Revenue estimate

33.3M

Past earnings

11 Aug 2026
EPS actual
-0.14 (+28.8%)
estimate -0.20
Revenue actual
5.7M
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.13 (+48.5%)
estimate -0.25
Revenue actual
4.6M
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
10 Mar 2026
EPS actual
-0.20 (-566.7%)
estimate -0.03
Revenue actual
5.6M (-72.7%)
estimate 20.5M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.26 (+29.7%)
estimate -0.37
Revenue actual
6.5M
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Prelude Therapeutics beat consensus estimates in its latest quarter, with EPS of negative $0.14 versus an estimate of negative $0.1967 and revenue of $5.7 million against an expected $0. Both EPS and revenue were also ahead of expectations in the prior quarter.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Krishna Vaddi
Employees
131
IPO date
25 Sep 2020
ISIN
US74065P1012
Website
preludetx.com

Frequently asked questions

When does Prelude Therapeutics Incorporated (PRLD) next report earnings?

Prelude Therapeutics Incorporated (PRLD) is scheduled to report earnings on November 5, 2026.

What was Prelude Therapeutics Incorporated's most recent earnings date?

Prelude Therapeutics Incorporated (PRLD) last reported earnings on August 11, 2026.

Where is Prelude Therapeutics Incorporated stock listed?

Prelude Therapeutics Incorporated (PRLD) is listed on Nasdaq.